WO2021044437A1 - Co-cristaux d'olaparib et leur procédé de préparation - Google Patents

Co-cristaux d'olaparib et leur procédé de préparation Download PDF

Info

Publication number
WO2021044437A1
WO2021044437A1 PCT/IN2020/050765 IN2020050765W WO2021044437A1 WO 2021044437 A1 WO2021044437 A1 WO 2021044437A1 IN 2020050765 W IN2020050765 W IN 2020050765W WO 2021044437 A1 WO2021044437 A1 WO 2021044437A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal
olaparib
fumaric acid
depicted
residue
Prior art date
Application number
PCT/IN2020/050765
Other languages
English (en)
Inventor
Srinivas Laxminarayan Pathi
Ramanaiah CHENNURU
Manjunath BOLLINENI
Original Assignee
Cipla Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Limited filed Critical Cipla Limited
Publication of WO2021044437A1 publication Critical patent/WO2021044437A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring

Definitions

  • the present invention relates to the novel cocrystalline forms of Olaparib, their methods of preparation and pharmaceutical compositions comprising said cocrystalline forms.
  • Lynparza is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated for (1) the treatment of certain patients with BRCA-mutated (as detected by an FDA-approved test) ovarian cancer or breast cancer, and (2) for the maintenance treatment of certain patients with ovarian cancer.
  • PARP poly(ADP-ribose) polymerase
  • Olaparib was developed and first dosed into patients by the UK-based biotechnology company, KuDOS Pharmaceuticals, which was later in 2006 was acquired by AstraZeneca.
  • Olaparib is chemically known as (4-[3-(4-cyclopropanecarbonyl-piperazine-l- carbonyl)-4-fluorobenzyl]-2H -phthalazin-2-one). Olaparib was first described in U.S. Pat. No. 7,449,464, and has the following chemical structure:
  • Pharmaceutical active ingredients can exist in a variety of distinct solid forms, including polymorphs, solvates, hydrates, salts, co-crystals and amorphous solids. Each form displays unique physicochemical properties that can profoundly influence the bioavailability, manufacturability purification, stability and other performance characteristics of the drugs.
  • Crystalline forms of Olaparib can possess advantageous properties in terms of their solubility and/or stability and/or bioavailability and/or impurity profile and/or filtration characteristics and/or drying characteristics and/or their ability to be handled and/or micronized and/or preparation of solid oral forms.
  • Form A Two crystalline forms of Olaparib, defined as form A and form L, are known in the literature.
  • a solvated form of form A is also known.
  • US 2017/0174662 A1 discloses amorphous and hydrated crystalline Form B of Olaparib and are characterized by XRD, DSC and IR.
  • WO 2017/153958 A1 patent application publication discloses crystalline Form M of Olaparib characterized by XRD, DSC and TGA. Due to low solubility in water, Olaparib has a low dissolution rate and as a result exhibits poor bioavailability. Hence, it is necessary to find crystal form with high solubility with improve efficiency of the drug.
  • certain salts and certain co-crystals, of Olaparib show advantageous properties for use as medical application forms of Olaparib.
  • Preferred ones among these solid forms are those comprising Olaparib and the organic acid within the same crystalline phase (i.e, the organic acid forming a crystalline salt or co-crystal with Olaparib, such organic acids are also recalled as "co-former” in the following).
  • the present invention is directed to novel pharmaceutical compounds comprising Olaparib and organic acids, methods of preparing such pharmaceutical compounds, and methods of treating ovarian cancer or breast cancer with such pharmaceutical compounds.
  • the pharmaceutical compound may be a co-crystal.
  • a “Pharmaceutical Compound” is a single chemical entity comprising two or more different elements that have a unique and defined chemical structure.
  • Pharmaceutical Compounds consist of a fixed ratio of atoms that are held together in a defined spatial arrangement by ionic, covalent, hydrogen bonds, van der Waals forces or p- p interactions.
  • the elements of a Pharmaceutical Compound comprise Olaparib and organic acids, water, ions, solvents, or co-formers.
  • the pharmaceutical compounds according to the present invention represent a” drugable form of Olaparib with organic acids”.
  • A” drugable form as used herein is defined as any form (salt, amorphous, crystal (of a salt), co-crystal, solution, dispersion, mixture, etc.) that Olaparib with organic acids might take which still can be formulated into a pharmaceutical formulation usable as a medicament to treat a disease or a symptom.
  • the present invention provides novel synergistic pharmaceutical compounds of Olaparib with group of organic acids also recalled as "co-former”.
  • novel pharmaceutical compounds are relatively stable towards the moisture and humidity, thereby representing an amorphous or a crystalline form of pharmaceutical compound, thus enhancing the efficacy of the parent molecule in lower doses.
  • a co-crystal of Olaparib and fumaric acid in a first aspect, a co-crystal of Olaparib and fumaric acid, pharmaceutical compositions containing the co-crystal, and methods of administering the co-crystal to a patient for treating a disease, are provided.
  • a co-crystal of Olaparib and 3,5-dihydroxybenzoic acid in a second aspect, a co-crystal of Olaparib and 3,5-dihydroxybenzoic acid, pharmaceutical compositions containing the co-crystal, and methods of administering the co-crystal to a patient for treating a disease, are provided.
  • co-crystals of the present invention could be either in a crystalline or amorphous form.
  • the co-crystals of Olaparib of the present invention have been characterized by means of Powder X-ray diffraction pattern (PXRD) and differential scanning calorimetry (DSC).
  • PXRD Powder X-ray diffraction pattern
  • DSC differential scanning calorimetry
  • a variety of other solid state spectroscopic techniques can be used including, but not limited to,, Raman spectroscopy, FTIR spectroscopy, vibrational spectroscopy, polarized light microscopy (PLM), and solid state NMR, the 13 C NMR and 3 ⁇ 4 NMR (in a suitable solvent, e.g., in D2O or DMSO-i3 ⁇ 4 ) to evaluate the chemical structure, Dynamic Gravimetric Vapor Sorption (DVS) to evaluate the hygroscopicity, thermogravimetric analysis (TGA) to evaluate the thermal properties, and/or chromatography (e.g, HPLC) in a suitable solvent to evaluate the purity.
  • Products as described herein
  • co-crystals of the present invention could be used for the preparation of Olaparib in the free base form or in the form of any other co-crystals of Olaparib.
  • FIG. 1 is an X-ray powder diffractogram of Olaparib- fumaric acid (1 : 1) cocrystal.
  • FIG. 2 is a DSC comparison of Olaparib- fumaric acid (1 : 1) co-crystal Vs Olaparib Vs fumaric acid
  • FIG. 3 is an X-ray powder diffractogram of Olaparib- 3,5-dihydroxybenzoic acid (1:1) co-crystal.
  • FIG. 4 is a DSC comparison of Olaparib- 3,5-dihydroxybenzoic acid (1:1) co crystal Vs Olaparib Vs 3,5-dihydroxy benzoic acid.
  • FIG. 5 is an X-ray powder diffractogram of amorphous Olaparib.
  • FIG. 6 is a mDSC curve of amorphous Olaparib.
  • Fig. 7 is a TGA curve of Olaparib- fumaric acid (1 : 1) co-crystal.
  • Fig. 8 is an Infrared spectrum of Olaparib- fumaric acid (1:1) co-crystal.
  • Fig. 9 is r ⁇ solubility of Olaparib- fumaric acid (1 : 1) co-crystal Vs Form-A at pH 1.2
  • Fig. 10 is r ⁇ solubility of Olaparib- fumaric acid (1 : 1) co-crystal Vs Form-A at pH 4.5
  • Fig. 11 is r ⁇ solubility of Olaparib- fumaric acid (1 : 1) co-crystal Vs Form-A at pH 6.8
  • compositions can be defined as crystalline materials comprised of an API and one or more unique co-crystal formers, which are solids at room temperature.
  • a new solid form is created having different properties from the Olaparib or the conformer.
  • a co crystal may have a different melting point, dissolution, solubility, hygroscopicity, bioavailability, toxicity, crystal morphology, density, loading volume, compressibility, physical stability, chemical stability, shelf life, taste, production costs, and/or manufacturing method than the drug.
  • co-former refers to a compound other than Olaparib that is also a component of the co-crystal. Thus, the co-former is part of the co-crystalline lattice.
  • the co-former is typically a GRAS (generally regarded as safe) compound and need not exhibit any therapeutic or pharmacological activity of its own.
  • co-former is selected from one or more pharmaceutically acceptable organic acids.
  • pharmaceutically acceptable organic acids see Handbook of Pharmaceutical Salts - Properties, Selection, and Use, P. Heinrich Stahl, CamiUe G. Wermuth (Eds.) VHCA (Verlag Helvetica Chemica Acta - Ziirich), Wiley-VCH (New York) 2002, which is incorporated herein by reference.
  • Organic acids are preferably selected from but not limited to the group comprising of fumaric acid and 3,5-dihydroxy benzoic acid.
  • the present co-crystal typically comprises Olaparib and the organic acid within the same crystalline phase in a molar ratio ranging from 1 :0.8 to 1:1.2.
  • co-crystal of Olaparib and fumaric acid.
  • co-crystal is mono fumaric acid co-crystal.
  • the mono- fumaric acid co-crystal can, in certain embodiments, be in hydrated or solvated form.
  • the co-crystal comprises Olaparib and the fumaric acid within the same crystalline phase in a molar ratio ranging from 1 :0.8 to 1 : 1.2. More preferably the co-crystal comprises Olaparib and the fumaric acid within the same crystalline phase in a molar ratio of 1 : 1.
  • the fumaric acid co-crystal of olaparib can be characterized as having peaks in X-ray powder diffraction patterns obtained therefrom.
  • co-crystal can be characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 6.60, 9.43, 13.22, 15.63, 17.20 and 19.98 ⁇ 0.2°20.
  • the XRPD diffractogram may comprise further peaks at 12.37, 14.30, 18.76, 19.19 and 28.44 ⁇ 0.2°20.
  • the fumaric acid co-crystal of Olaparib is characterized by having an XRD pattern as shown in Figure 1.
  • the fumaric acid co-crystal of Olaparib may also be characterized as having a DSC spectrum exhibiting onset melting point at around 193.86°C.
  • fumaric acid co-crystal of Olaparib may is characterized by having a DSC spectrum as shown in Figure 2. In an embodiment, fumaric acid co-crystal of Olaparib is characterized by having a thermogravimetric analysis as shown in Figure 7.
  • fumaric acid co-crystal of Olaparib may also be characterized as having an IR spectrum comprising characteristics IR spectra peaks at about 1202 cm 1 , 1231 cm 1 , 1242 cm 1 , 1262 cm 1 , 1281 cm 1 , 1639 cm 1 and 1695 cm 1 ( ⁇ 3 cm 1 ).
  • FT-IR Infrared
  • fumaric acid co-crystal of Olaparib is characterized by having an IR spectrum as shown in Figure 8.
  • fumaric acid co-crystal of Olaparib is characterized by having powder dissolution profile as shown in any one of Figures 9 to 11.
  • a process for preparing fumaric acid co-crystal of Olaparib comprising, a. dissolving Olaparib and fumaric acid in a suitable solvent selected from the group comprising of C1-C4 alcohol or a mixture of C1-C4 alcohols thereof; b. removing the solvent under reduced pressure to obtain a residue; c. cooling the residue to a temperature ranging from about 20°C to 30°C; and d. isolating the precipitated fumaric acid co-crystal of Olaparib and drying at 25-50°C, preferably at 30-40°C for at least 1 hr.
  • the alcohol solvent in step (a) comprises one or more of methanol, ethanol, isopropanol, n-propanol, n-butanol, t-butanol and the like.
  • co-crystal of Olaparib and 3,5- dihydroxybenzoic acid.
  • co-crystal is mono 3,5- dihydroxybenzoic acid co-crystal.
  • the mono 3,5-dihydroxybenzoic acid co-crystal can, in certain embodiments, be in hydrated or solvated form.
  • the co crystal comprises Olaparib and 3,5-dihydroxybenzoic within the same crystalline phase in a molar ratio ranging from 1 :0.8 to 1.1.2.
  • the 3,5-dihydroxybenzoic acid co-crystals can be characterized as having peaks in X-ray powder diffraction patterns obtained therefrom.
  • one salt can be characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 9.59, 13.63, 17.84, 19.12, 20.86 and 25.43 ⁇ 0.2 °20.
  • the XRPD diffractogram may comprise further peaks at 7.88, 11.18, 22.37 and 23.65 ⁇ 0.2°20.
  • the 3,5-dihydroxybenzoic acid co-crystal of Olaparib is characterized by having an XRD pattern as shown in Figure 3.
  • the 3,5-dihydroxybenzoic acid co-crystal of Olaparib may also be characterized as having a DSC spectrum exhibiting onset melting point at around 172.06°C.
  • 3,5-dihydroxybenzoic acid co-crystal of Olaparib may is characterized by having a DSC spectrum as shown in Figure 4.
  • a process for preparing 3,5-dihydroxybenzoic acid co-crystal of Olaparib comprising, a. dissolving Olaparib and 3,5-dihydroxybenzoic acid in a suitable solvent selected from the group comprising of C1-C4 alcohol or a mixture of Cl- C4 alcohol thereof; b. removing the solvent under reduced pressure to obtain a residue; c. cooling the reaction mass to a temperature ranging from about 20°C to 30°C; d.
  • a solvent or a solvent mixture selected from the group comprising of polar and non-polar solvent such as ethyl acetate, methyl acetate, isopropyl acetate, dimethyl ether, diethyl ether, di-isopropyl ether, hexane, heptane and pentane, for at about 20 hours to about 50 hours; and e. isolating the precipitated 3,5-dihydroxybenzoic acid co-crystal of Olaparib and drying under reduced pressure at 30-50°C, preferably at 35-45°C for at least 1 hr.
  • polar and non-polar solvent such as ethyl acetate, methyl acetate, isopropyl acetate, dimethyl ether, diethyl ether, di-isopropyl ether, hexane, heptane and pentane
  • the alcohol solvent in step (a) comprises one or more of methanol, ethanol, isopropanol, n-propanol, n-butanol, t-butanol and the like.
  • a novel process to prepare amorphous Olaparib comprising, a. dissolving Olaparib in a suitable solvent selected from the group comprising of C1-C4 alcohols such as methanol, ethanol, isopropanol, n-butanol, t- butanol; ketones such as acetone, MIBK, or a mixture thereof; b. removing the solvent under reduced pressure to obtain a residue; c. cooling the residue to a temperature ranging from about 20°C to 30°C; and d. isolating the precipitated amorphous Olaparib and drying at 25-50°C, preferably at 30-40°C for at least 1 hr.
  • a suitable solvent selected from the group comprising of C1-C4 alcohols such as methanol, ethanol, isopropanol, n-butanol, t- butanol; ketones such as acetone, MIBK, or a mixture thereof.
  • the amorphous form of Olaparib has a XRPD pattern and mDSC curve and as shown in FIGS. 5 and 6 respectively.
  • the Olaparib used in the above processes, may be in any polymorphic form or in a mixture of any polymorphic forms.
  • the starting material can be obtained by any method known in the art, such as the one described in the US patent No. 7,449,464 which is incorporated herein by reference.
  • H-NMR reveals a molar ratio of Olaprib to 3,5-dihydroxybenzoic acid of about 1:1.
  • the powder X-ray diffraction pattern is depicted in Fig 3 and DSC in Fig 4.
  • the amorphous form has a XRPD pattern and mDSC curve and as shown in FIGS. 5 and 6 respectively.
  • Powder dissolution studies were performed for Olaparib Form-A vs Olaparib- Fumaric acid (1:1) co-crystal. Prior to dissolution experiments, all the powder materials were smoothly ground and sieved with 60 mesh to reduce the impact of particle size on the dissolution study. Powder dissolution studies were conducted for Form-A and Olaparib-Fumaric acid (1:1) co-crystal in different biological buffers (pH 1.2, pH 4.5, and pH 6.8) over different time intervals (15, 30, 60, 120, 240 and 1440 minutes).
  • Table 2 shows pH solubility of Olaparib-Fumaric acid (1:1) co-crystal Vs Form-A at pH 1.2 in tabular form.
  • Table 3 shows pH solubility of Olaparib-Fumaric acid (1:1) co-crystal Vs Form-A at pH 4.5 in tabular form.
  • Table 4 shows pH solubility of Olaparib-Fumaric acid (1:1) co-crystal Vs Form-A at pH 6.8 in tabular form.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne certains co-cristaux d'olaparib et fournit de nouvelles formes polymorphes de certains co-cristaux d'olaparib. En particulier, l'invention concerne des cocristaux d'olaparib avec de l'acide fumarique et de l'acide 3,5-dihydroxybenzoïque. L'invention concerne en outre des procédés de préparation et de caractérisation de tels cocristaux d'olaparib. De plus, la présente invention concerne une composition pharmaceutique contenant les cocristaux d'olaparib et un procédé de traitement de troubles chez un patient en ayant besoin, comprenant l'administration d'une quantité thérapeutiquement efficace de ladite composition.
PCT/IN2020/050765 2019-09-04 2020-09-02 Co-cristaux d'olaparib et leur procédé de préparation WO2021044437A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921035551 2019-09-04
IN201921035551 2019-09-04

Publications (1)

Publication Number Publication Date
WO2021044437A1 true WO2021044437A1 (fr) 2021-03-11

Family

ID=72840601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2020/050765 WO2021044437A1 (fr) 2019-09-04 2020-09-02 Co-cristaux d'olaparib et leur procédé de préparation

Country Status (1)

Country Link
WO (1) WO2021044437A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113636979A (zh) * 2021-08-12 2021-11-12 天津理工大学 一种奥拉帕尼与富马酸共晶晶型α及其制备方法与应用
WO2022058785A1 (fr) 2020-09-16 2022-03-24 Nuformix Technologies Limited Co-cristaux d'acide oxalique olaparib et leur utilisation pharmaceutique
CN115197152A (zh) * 2022-07-11 2022-10-18 江苏海洋大学 一种奥拉帕尼药物共晶及其制备方法和应用
WO2023084311A1 (fr) 2021-11-10 2023-05-19 Nuformix Technologies Limited Co-cristaux d'acide hydroxybenzoïque d'olaparib et leur utilisation pharmaceutique
US12012386B2 (en) 2021-09-14 2024-06-18 Nuformix Technologies Limited Olaparib oxalic acid cocrystals and their pharmaceutical use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059663A1 (en) * 2003-03-12 2005-03-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2008047082A2 (fr) * 2006-10-17 2008-04-24 Kudos Pharmaceuticals Limited Dérivé de phtalazinone
US20100286157A1 (en) 2007-10-17 2010-11-11 Kudos Pharmaceuticals Limited 4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbonyl) -4 -fluoro-benzyl] -2h-phthalaz in-1-one
US20170174662A1 (en) 2015-12-22 2017-06-22 Olon S.P.A. Crystalline and amorphous forms of olaparib
WO2017153958A1 (fr) 2016-03-11 2017-09-14 Lupin Limited Nouvelles formes polymorphes et forme amorphe d'olaparib

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059663A1 (en) * 2003-03-12 2005-03-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2008047082A2 (fr) * 2006-10-17 2008-04-24 Kudos Pharmaceuticals Limited Dérivé de phtalazinone
US8247416B2 (en) 2006-10-17 2012-08-21 Kudos Pharmaceuticals Limited Phthalazinone derivative
US20100286157A1 (en) 2007-10-17 2010-11-11 Kudos Pharmaceuticals Limited 4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbonyl) -4 -fluoro-benzyl] -2h-phthalaz in-1-one
US20170174662A1 (en) 2015-12-22 2017-06-22 Olon S.P.A. Crystalline and amorphous forms of olaparib
WO2017153958A1 (fr) 2016-03-11 2017-09-14 Lupin Limited Nouvelles formes polymorphes et forme amorphe d'olaparib

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Salts - Properties, Selection, and Use", 2002, VHCA

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022058785A1 (fr) 2020-09-16 2022-03-24 Nuformix Technologies Limited Co-cristaux d'acide oxalique olaparib et leur utilisation pharmaceutique
JP2023538455A (ja) * 2020-09-16 2023-09-07 ナフォーミックス テクノロジーズ リミテッド オラパリブシュウ酸共結晶及びその医薬的使用
JP7453475B2 (ja) 2020-09-16 2024-03-19 ナフォーミックス テクノロジーズ リミテッド オラパリブシュウ酸共結晶及びその医薬的使用
CN113636979A (zh) * 2021-08-12 2021-11-12 天津理工大学 一种奥拉帕尼与富马酸共晶晶型α及其制备方法与应用
US12012386B2 (en) 2021-09-14 2024-06-18 Nuformix Technologies Limited Olaparib oxalic acid cocrystals and their pharmaceutical use
WO2023084311A1 (fr) 2021-11-10 2023-05-19 Nuformix Technologies Limited Co-cristaux d'acide hydroxybenzoïque d'olaparib et leur utilisation pharmaceutique
CN115197152A (zh) * 2022-07-11 2022-10-18 江苏海洋大学 一种奥拉帕尼药物共晶及其制备方法和应用

Similar Documents

Publication Publication Date Title
WO2021044437A1 (fr) Co-cristaux d'olaparib et leur procédé de préparation
RU2162468C2 (ru) Моногидрат гидрохлорида 1-циклопропил-7-([s,s]-2,8-диазабицикло[4.3.0]нон-8-ил)-6-фтор-1,4-дигидро -8-метокси-4-оксо-3-хинолинкарбоновой кислоты и фармацевтическая композиция с антибактериальной активностью
EP2791141B1 (fr) Sel de mono-tartrate de Tofacitinib
CN113993853A (zh) 氯苯唑酸及其盐的固态形式
HUE026408T2 (en) Dabigatran etexylate bis-mesylate salt, solid forms and process for their preparation
EP3743405B1 (fr) Acide fumarique siponimod cristallin et polymorphes de celui-ci
AU2011334928B2 (en) Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
EP2817303A2 (fr) Formes solides d'étéxilate-mésylate de dabigatran et procédés pour leur préparation
US10023577B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
WO2011007870A1 (fr) Benzène-sulfonate de 2-[[[2-[(hydroxyacétyl)amino]-4-pyridinyl]méthyl]thio]-n-[4-(trifluorométhoxy)phényl]-3-pyridinecarboxamide, cristaux de celui-ci, ses polymorphes et ses procédés de fabrication
AU2018234306B2 (en) Salts of antiviral phosphonate analogues and process for preparation thereof
US20090202647A1 (en) Solid form of racemic rotigotine
US20150087686A1 (en) Crystalline forms of saxagliptin
JP7450842B2 (ja) フェニルピリミドン化合物の塩、結晶多形並びにその医薬組成物及び使用
JP2023506025A (ja) レンボレキサントの固体形態
EP3710425A1 (fr) Formes à l'état solide d'elafibranor
EP3184516A1 (fr) Complexe d'inclusion crystallin de mirabegron avec beta-cyclodextrine
WO2022224269A1 (fr) Co-cristaux, sels et formes solides de niraparib
EP4103560A1 (fr) Nouveaux sels de nilotinib et formes polymorphes de celui-ci
WO2023043869A1 (fr) Formes à l'état solide de citrate d'ipatasertib
CN115298169A (zh) (1r,3s)-3-(5-氰基-4-苯基-1,3-噻唑-2-基氨基甲酰基)环戊烷羧酸的共晶
WO2024062344A1 (fr) Formes à l'état solide de mesdopétam et leurs sels
US20100152142A1 (en) Crystalline form ii of tigecycline and processes for preparation thereof
WO2023223205A1 (fr) Formes à l'état solide de mirdamétinib et leur procédé de préparation
EP4085062A1 (fr) Nouveaux sels et/ou co-cristaux de ténofovir alafénamide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20790079

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20790079

Country of ref document: EP

Kind code of ref document: A1